Reivindicaciones

CLAIMS: 1. 1. Substantially pure Crambescidin 834. 2. 2. Substantially pure Crambescidin 818. 3. 3. Substantially pure Crambescidin 673. 4. 4. Substantially pure Crambescidin 687. 5. 5. Substantially pure Crambescidin 657. 6. 6. Substantially pure 13,14,15 Isocrambescidin 657. 7. 7. Substantially pure methyl Crambescidin 657. 8. 8. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 834 and a pharmaceutically acceptable carrier, diluent or excipient. 9. 9. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 818 and a pharmaceutically acceptable carrier, diluent or excipient. 10. 10. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 673 and a pharmaceutically acceptable carrier, diluent or excipient. 11. 11. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 687 and a pharmaceutically acceptable carrier, diluent or excipient. 12. 12. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 13. 13. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as 13,14,15 Isocrambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 14. 14. A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as methyl Crambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 15. 15. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 834 and a pharmaceutically acceptable carrier, diluent or excipient. 16. 16. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 818 and a pharmaceutically acceptable carrier, diluent or excipient. 17. 17. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 673 and a pharmaceutically acceptable carrier, diluent or excipient. 18. 18. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 687 and a pharmaceutically acceptable carrier, diluent or excipient. 19. 19. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Crambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 20. 20. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as 13,14,15 Isocrambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient. 21. 21. The use for the manufacture of a medicament for the therapeutic or prophylactic treatment of a patient suffering from a mammalian tumor, of an effective antitumor amount of the substantially pure compound designated herein as Methyl Crambescidin 657 and a pharmaceutically acceptable carrier, diluent or excipient.